Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7–30. PubMed PMID: 29313949.
   PubMed Web of Science ®Google Scholar
• Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22(Suppl 6):vi35–9. PubMed PMID: 21908501.
   PubMedGoogle Scholar
• Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006 Oct 10;24(29):4783–4791. PubMed PMID: 17028294.
   PubMed Web of Science ®Google Scholar
• Bondi C, Barra F, Ferrero S. Epidemiology and risk factors. In: Ferrero S, editor. Endometrial cancer: risk factors, management and prognosis. New York (NY): Nova science publisher; 2018:1-24.
   Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–17. PubMed PMID: 6822361.
   PubMed Web of Science ®Google Scholar
• Tsikouras P, Bouchlariotou S, Vrachnis N, et al. Endometrial cancer: molecular and therapeutic aspects. Eur J Obstet Gynecol Reprod Biol. 2013 Jul;169(1):1–9. PubMed PMID: 23433742.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67–73. PubMed PMID: 23636398; PubMed Central PMCID: PMCPMC3704730.
   PubMed Web of Science ®Google Scholar
• Suri V, Arora A. Management of endometrial cancer: a review. Rev Recent Clin Trials. 2015;10(4):309–316. PubMed PMID: 26411949.
   PubMed Web of Science ®Google Scholar
• Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi33–8. PubMed PMID: 24078661.
   PubMed Web of Science ®Google Scholar
• Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009 Jan;16(1):38–45. PubMed PMID: 19078928.
   PubMed Web of Science ®Google Scholar
• Oehler MK, Fung A, Jobling TW. Advances in the treatment of endometrial cancer. J Br Menopause Soc. 2005 Mar;11(1):18–22. PubMed PMID: 15814058.
   PubMedGoogle Scholar
• Le Gallo M, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem. 2014 Jan;60(1):98–110. PubMed PMID: 24170611; PubMed Central PMCID: PMCPMC4128551.
   PubMed Web of Science ®Google Scholar
• Barra F, Evangelisti G, Damiano G, et al. New perspectives with targeted drugs. In: Ferrero S, editor. Endometrial cancer: risk factors, management and prognosis. New York (NY): Nova science publisher; 2018:301-314.
   Google Scholar
• Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2012 Nov 1;18(21):5856–5864. PubMed PMID: 23082003.
   PubMed Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016 Jan;27(1):16–41. PubMed PMID: 26634381.
   PubMed Web of Science ®Google Scholar
• Shih KK, Yun E, Gardner GJ, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol. 2011 Sep;122(3):608–611. PubMed PMID: 21664663.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018 Feb;16(2):170–199. PubMed PMID: 29439178.
   PubMed Web of Science ®Google Scholar
• Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol. 2001 Apr;15(2):265–278. PubMed PMID: 11358401.
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2006 Jan 1;24(1):36–44. PubMed PMID: 16330675.
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a gynecologic oncology group study. Gynecol Oncol. 2009 Mar;112(3):543–552. PubMed PMID: 19108877; PubMed Central PMCID: PMCPMC4459781.
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;125(3):771.
   Web of Science ®Google Scholar
• Sovak MA, Dupont J, Hensley ML, et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer. 2007 Jan-Feb;17(1):197–203. PubMed PMID: 17291253.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008 May;109(2):250–254. PubMed PMID: 18299146.
   PubMed Web of Science ®Google Scholar
• Sorbe B, Andersson H, Boman K, et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):803–808. PubMed PMID: 17944917.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J clin oncol. 2004;22(11):2159–2166. PubMed PMID: 15169803.
   PubMed Web of Science ®Google Scholar
• Makker V, Hensley ML, Zhou Q, et al. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer. 2013 Jun;23(5):929–934. PubMed PMID: 23598889; PubMed Central PMCID: PMCPMC3694716.
   PubMed Web of Science ®Google Scholar
• Grisham RN, Adaniel C, Hyman DM, et al. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial Sloan-Kettering Cancer Center experience. Int J Gynecol Cancer. 2012 Jun;22(5):807–811. PubMed PMID: 22635030; PubMed Central PMCID: PMCPMC3904291.
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013 Dec;131(3):567–573. PubMed PMID: 24076450.
   PubMed Web of Science ®Google Scholar
• Moore KN, Chunqiao T, Scott MD, et al. Does the progression‐free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer. 2010;116(23):5407–5414.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol. 1999 Jun;17(6):1736–1744. PubMed PMID: 10561210.
   PubMed Web of Science ®Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):964–978. PubMed PMID: 17442022.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001 Jan 15;19(2):364–367. PubMed PMID: 11208827.
   PubMed Web of Science ®Google Scholar
• Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada clinical trials group. Int J Gynecol Cancer. 2004 Jul-Aug;14(4):650–658. PubMed PMID: 15304161.
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2000 Aug;78(2):212–216. PubMed PMID: 10926805.
   PubMed Web of Science ®Google Scholar
• Bogliolo S, Cassani C, Dominoni M, et al. The role of fulvestrant in endometrial cancer. Expert Opin Drug Metab Toxicol. 2017 May;13(5):537–544. PubMed PMID: 27696906.
   PubMed Web of Science ®Google Scholar
• Secord AA, Geller MA, Broadwater G, et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol. 2013 Jan;128(1):65–70. PubMed PMID: 23085460.
   PubMed Web of Science ®Google Scholar
• Klopp AH, Jhingran A, Ramondetta L, et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009;115(1):6–11.
   PubMed Web of Science ®Google Scholar
• Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – results from two randomised studies. Eur J Cancer. 2010 Sep;46(13):2422–2431. PubMed PMID: 20619634; PubMed Central PMCID: PMCPMC3552301.
   PubMed Web of Science ®Google Scholar
• Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015 Jun;93:52–79. PubMed PMID: 25813885.
   PubMed Web of Science ®Google Scholar
• Barra F, Lorusso D, Leone Roberti Maggiore U, et al. Investigational drugs for the treatment of cervical cancer. Expert Opin Investig Drugs. 2017 Apr;26(4):389–402. PubMed PMID: 28274154.
   PubMed Web of Science ®Google Scholar
• Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol. 2012 Oct;17(5):430–440. PubMed PMID: 22926640.
   PubMed Web of Science ®Google Scholar
• Vellone G, Peñuela L, Carbone R, et al. Molecular pathology of endometrial carcinoma and its histopathological correlations: beyond a dualistic vision? In: Ferrero S, editor. Endometrial cancer: risk factors, management and prognosis. New York (NY): Nova science publisher; 2018:25-68.
   Google Scholar
• Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014 Jun;15(7):e268–78. PubMed PMID: 24872110.
   PubMed Web of Science ®Google Scholar
• Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015 Apr;28(4):505–514. PubMed PMID: 25394778.
   PubMed Web of Science ®Google Scholar
• Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 2015 Jan;107(1):402. PubMed PMID: 25505230; PubMed Central PMCID: PMCPMC4301706. eng.
   PubMedGoogle Scholar
• Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell. 2013 Nov 7;155(4):858–868. PubMed PMID: 24209623; PubMed Central PMCID: PMCPMC3871995. eng.
   PubMed Web of Science ®Google Scholar
• Sagae S, Susumu N, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83–S89. PubMed PMID: 25341586; eng.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006 Aug;7(8):606–619. PubMed PMID: 16847462.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease. Cell. 2017 Aug 10;170(4):605–635. PubMed PMID: 28802037; PubMed Central PMCID: PMCPMC5726441.
   PubMed Web of Science ®Google Scholar
• DiNitto JP, Cronin TC, Lambright DG. Membrane recognition and targeting by lipid-binding domains. Sci STKE. 2003 Dec 16;2003(213):re16. PubMed PMID: 14679290; eng.
   PubMedGoogle Scholar
• Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (New York, NY). 2005 Feb 18;307(5712):1098–1101. PubMed PMID: 15718470; eng.
   Google Scholar
• Polivka J Jr., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014 May;142(2):164–175. PubMed PMID: 24333502.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007 Nov 15;67(22):10804–10812. PubMed PMID: 18006825.
   PubMed Web of Science ®Google Scholar
• Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014 Mar;138(3):343–350. PubMed PMID: 24576030.
   PubMed Web of Science ®Google Scholar
• Getz G, Gabriel SB, Cibulskis K, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
   PubMed Web of Science ®Google Scholar
• Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010 Apr;7(4):209–219. PubMed PMID: 20234352; eng.
   PubMed Web of Science ®Google Scholar
• Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143–144. PubMed PMID: 9326929; eng.
   PubMed Web of Science ®Google Scholar
• Peiro G, Peiro FM, Ortiz-Martinez F, et al. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Hum Pathol. 2013 Feb;44(2):218–225. PubMed PMID: 22955108.
   PubMed Web of Science ®Google Scholar
• Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011 Mar 15;17(6):1331–1340. PubMed PMID: 21266528; PubMed Central PMCID: PMCPMC3060282. eng.
   PubMed Web of Science ®Google Scholar
• Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011 Jul;1(2):170–185. PubMed PMID: 21984976; PubMed Central PMCID: PMCPMC3187555.
   PubMed Web of Science ®Google Scholar
• Urick ME, Rudd ML, Godwin AK, et al. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011 Jun 15;71(12):4061–4067. PubMed PMID: 21478295; PubMed Central PMCID: PMCPMC3117071.
   PubMed Web of Science ®Google Scholar
• Shoji K, Oda K, Nakagawa S, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009 Jul 7;101(1):145–148. PubMed PMID: 19491896; PubMed Central PMCID: PMCPMC2713716.
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011 Jun;36(6):320–328. PubMed PMID: 21531565; PubMed Central PMCID: PMCPMC3112285.
   PubMed Web of Science ®Google Scholar
• Koul A, Willen R, Bendahl PO, et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 2002 May 1;94(9):2369–2379. PubMed PMID: 12015762.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 1;22(15):3126–3132. PubMed PMID: 15284264.
   PubMed Web of Science ®Google Scholar
• Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007 Nov 1;26(50):7158–7162. PubMed PMID: 17525745; PubMed Central PMCID: PMCPMC2871595.
   PubMed Web of Science ®Google Scholar
• Livasy CA, Reading FC, Moore DT, et al. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006 Jan;100(1):101–106. PubMed PMID: 16157366.
   PubMed Web of Science ®Google Scholar
• Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994 Apr;53(1):84–92. PubMed PMID: 7909788.
   PubMed Web of Science ®Google Scholar
• McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006 Nov 1;12(21):6373–6378. PubMed PMID: 17085648.
   PubMed Web of Science ®Google Scholar
• Jessen K, Kessler L, Kucharski J, et al. Abstract A171: a potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. Mol Cancer Ther. 2011;10(11 Supplement):A171–A171.
   Google Scholar
• Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 7;454(7205):776–779. PubMed PMID: 18594509; PubMed Central PMCID: PMCPMC2750091.
   PubMed Web of Science ®Google Scholar
• Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol. 2010;28(15_suppl):3005.
   Google Scholar
• Wagner AJ, Bendell JC, Dolly S, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol. 2011;29(15_suppl):3020. PubMed PMID: 28022675.
   Web of Science ®Google Scholar
• Yap TA, Bjerke L, Clarke PA, et al. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015 Aug;23:98–107. PubMed PMID: 26117819; PubMed Central PMCID: PMCPMC4728196.
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Blouin M-J, Piura E, et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010 August 01;123(1):271–279.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol. 2011;29(24):3278–3285.
   PubMed Web of Science ®Google Scholar
• Goodwin RA, Jamal R, Tu D, et al. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2013;131(2):315–320.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10;33(8):930–936. PubMed PMID: 25624430; PubMed Central PMCID: PMCPMC4348638.
   PubMed Web of Science ®Google Scholar
• Soliman PT, Westin SN, Iglesias DA, et al. Phase II study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer. J Clin Oncol. 2016 May 20;34(15_suppl):5506.
   Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Mar;132(3):585–592. PubMed PMID: 24456823; PubMed Central PMCID: PMCPMC4063288.
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2007;25(18_suppl):5516.
   Google Scholar
• Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014 Nov;135(2):184–189. PubMed PMID: 25173583.
   PubMed Web of Science ®Google Scholar
• Morotti M, Valenzano Menada M, Venturini PL, et al. Bevacizumab in endometrial cancer treatment. Expert Opin Biol Ther. 2012 May;12(5):649–658. PubMed PMID: 22428875.
   PubMed Web of Science ®Google Scholar
• Bogliolo S, Cassani C, Gardella B, et al. Current opinion on bevacizumab on endometrial cancer treatment. Expert Opin Biol Ther. 2015 Feb;15(2):299–307. PubMed PMID: 25539414.
   PubMed Web of Science ®Google Scholar
• Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2013 Apr;129(1):22–27. PubMed PMID: 23262204.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci VL, Dizon DS, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015 May 20;33(15_suppl):5500.
   Web of Science ®Google Scholar
• Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb;136(2):246-253. PMID:25528496.
   Google Scholar
• Heudel PE, Fabbro M, Roemer-Becuwe C, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br J Cancer. 2017 Jan;116(3):303-309. PubMed PMID: 28072765.
   Google Scholar
• Myers AP, Broaddus R, Makker V, et al. Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J Clin Oncol. 2013 May 20;31(15_suppl):5524.
   Web of Science ®Google Scholar
• Shoji K, Oda K, Kashiyama T, et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One. 2012;7(5):e37431 PubMed PMID: 22662154.
   Google Scholar
• Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18351–18356. PubMed PMID: 19805051; PubMed Central PMCID: PMCPMC2757399.
   PubMed Web of Science ®Google Scholar
• Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009 Sep;1(6–7):315–322. PubMed PMID: 20049735; PubMed Central PMCID: PMCPMC3378149.
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012 Nov;2(11):1036–1047. PubMed PMID: 22915752; PubMed Central PMCID: PMCPMC5125254.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010 Oct 13;2(53):53ra75. PubMed PMID: 20944090.
   PubMed Web of Science ®Google Scholar
• English DP, Roque DM, Carrara L, et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol. 2013 Dec;131(3):753–758. PubMed PMID: 24012800.
   PubMed Web of Science ®Google Scholar
• Lopez S, Schwab CL, Cocco E, et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014 Nov;135(2):312–317. PubMed PMID: 25172762; PubMed Central PMCID: PMCPMC4270135.
   PubMed Web of Science ®Google Scholar
• Chapman NM, Chi H. mTOR signaling, tregs and immune modulation. Immunotherapy. 2014;6(12):1295–1311. PubMed PMID: 25524385; PubMed Central PMCID: PMCPMC4291176.
   PubMed Web of Science ®Google Scholar
• Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 7;16(1):21–32. PubMed PMID: 19573809; PubMed Central PMCID: PMCPMC2752826.
   PubMed Web of Science ®Google Scholar